On November 12, the next meeting of the AOTMiT Transparency Council?
The agenda includes:
- Preparation of a position paper on the evaluation of the drug Amvuttra (vutrisiran) under the drug program: "Treatment of adult patients with stage I or II polyneuropathy in the course of hereditary transthyretin amyloidosis (ICD-10 E85.1)". ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in